106 articles on gene editing and biotech
NAD+ levels decline with age, and NMN supplements promise to reverse it. But does the science hold up? Here's an honest, evidence-based look at what we know — and what we don't.
DNA editing is permanent. RNA editing is reversible. Both can treat disease. Here's why reversibility might be the safer path for many genetic conditions.
Current CAR-T therapies cost $400K+, take weeks to manufacture, and require each patient's own cells. Gene-edited 'off-the-shelf' CAR-T could treat any patient instantly — if scientists can solve the persistence problem.
AI is transforming gene editing — from designing better guide RNAs to engineering entirely new CRISPR proteins. Here's how the convergence of AI and CRISPR is accelerating genetic medicine.
Gene-edited tomatoes, soybeans, and lettuce are already on store shelves. Are they different from GMOs? Are they safe? Here's what the science says.
Editas Medicine was the first CRISPR company, co-founded by Feng Zhang with Broad Institute patents. But while competitors won FDA approvals, Editas struggled. Here's what happened.
Excision BioTherapeutics is using CRISPR to cut HIV DNA out of infected cells — the first gene editing approach that could truly cure, not just manage, HIV/AIDS.
Eli Lilly acquired Verve Therapeutics for $1.3 billion in July 2025 — the biggest signal yet that big pharma believes in one-time genetic cures for chronic diseases.
In 2018, He Jiankui created the world's first gene-edited babies. The scientific community condemned it. But the questions he raised — about enhancement, equity, and consent — haven't gone away.
Beta-thalassemia patients need blood transfusions every 2-4 weeks for life. Gene therapy is changing that — with Casgevy and Zynteglo already approved, and next-gen approaches in development.
CAR-T therapy costs $373,000-$475,000 per infusion and achieves 30-60% complete remission depending on cancer type. Here's the full breakdown of costs, outcomes, and what patients should know.
The gene editing market is projected to grow from $8.9 billion in 2024 to $45 billion by 2034 — a 17% CAGR. Here's where the growth is coming from and which segments will dominate.